The Clinical Effectiveness and Safety of Vaccinations against COVID-19 in HIV-Positive Patients: Data from Observational Study in Poland
暂无分享,去创建一个
[1] I. Boutron,et al. Efficacy and safety of COVID‐19 vaccines , 2022, The Cochrane database of systematic reviews.
[2] A. Horban,et al. Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center , 2022, Vaccines.
[3] A. Horban,et al. The Clinical Course and Outcomes of Patients Hospitalized Due to COVID-19 during Three Pandemic Waves in Poland: A Single Center Observational Study , 2022, Journal of clinical medicine.
[4] J. Kowalska,et al. Complementary dose of COVID-19 vaccination may prevent SARS-CoV-2 breakthrough infection among previously vaccinated HIV positive persons. , 2022, Przeglad Epidemiologiczny.
[5] William F. Fadel,et al. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study , 2022, BMJ.
[6] M. Gandhi,et al. COVID-19 Outcomes and Risk Factors Among People Living with HIV , 2022, Current HIV/AIDS Reports.
[7] G. Llauradó,et al. Individuals With Higher CD4/CD8 Ratio Exhibit Increased Risk of Acute Respiratory Distress Syndrome and In-Hospital Mortality During Acute SARS-CoV-2 Infection , 2022, Frontiers in Medicine.
[8] Jessie K. Edwards,et al. Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States , 2022, JAMA network open.
[9] B. Lu,et al. Acceptance of COVID-19 vaccination and influencing factors among people living with HIV in Guangxi, China: a cross-sectional survey , 2022, BMC Infectious Diseases.
[10] A. Horban,et al. The Presence of Either Typical or Atypical Radiological Changes Predicts Poor COVID-19 Outcomes in HIV-Positive Patients from a Multinational Observational Study: Data from Euroguidelines in Central and Eastern Europe Network Group , 2022, Viruses.
[11] A. Horban,et al. The Beneficial Effect of the COVID-19 Vaccine Booster Dose among Healthcare Workers in an Infectious Diseases Center , 2022, Vaccines.
[12] L. Galea,et al. Intention to Receive a COVID-19 Vaccine by HIV Status Among a Population-Based Sample of Women and Gender Diverse Individuals in British Columbia, Canada , 2021, AIDS and Behavior.
[13] Á. Soriano,et al. Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data , 2021, Infectious Diseases and Therapy.
[14] J. Tomažič,et al. National strategies for vaccination against COVID‐19 in people living with HIV in Central and Eastern European region , 2021, HIV medicine.
[15] Miguel Ángel Martínez,et al. Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study , 2021, The Lancet HIV.
[16] S. Madhi,et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial , 2021, The Lancet HIV.
[17] P. Klenerman,et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial , 2021, The Lancet HIV.
[18] A. Mastalerz-Migas,et al. Attitudes toward Vaccination against COVID-19 in Poland. A Longitudinal Study Performed before and Two Months after the Commencement of the Population Vaccination Programme in Poland , 2021, Vaccines.
[19] H. Fennema,et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.
[20] J. Biegel,et al. Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity , 2021, medRxiv.
[21] Nguyen H. Tran,et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.
[22] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[23] D. Cattaneo,et al. Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV , 2020, HIV medicine.
[24] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[25] V. Calvez,et al. Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.